Selective Estrogen Receptor Modulators (SERMs)

SERMs are a class of estrogen-related compounds that display selective agonism or antagonism at estrogen receptors (ERs) depending on the tissue. This category includes tamoxifen, raloxifene, bazedoxifene, clomiphene, and ospemifene.

Mechanism of Action

All SERMs bind to the ligand-binding pocket of both ERα and ERβ, competitively blocking estradiol binding. However, the key to tissue selectivity lies in how the receptor is bound:

When estrogen or a SERM binds, the ER adopts a different 3D conformation depending on the ligand.
Each conformation recruits different coactivators and corepressors at target gene promoters.
Combined with the fact that different tissues express different co-regulatory proteins, this creates tissue-specific agonist or antagonist effects.

Mechanism of steroid hormone action and antiestrogen drug action

Individual SERM Drug Profiles

1. Tamoxifen

Feature	Detail
Class	Triphenylethylene (same stilbene nucleus as diethylstilbestrol)
Receptor action	Antagonist in breast; partial agonist in uterus/endometrium and bone
Uses	ER+ breast cancer (treatment + adjuvant after mastectomy/radiotherapy); prophylaxis in high-risk women; male breast cancer
Metabolism	CYP3A4 and CYP2D6 → active metabolites (4-hydroxytamoxifen, endoxifen); excreted via bile into feces
PK note	CYP2D6 poor metabolizers produce less active metabolite → reduced efficacy
Drug interactions	Inhibitor of CYP3A4 and P-glycoprotein

Adverse effects:

Hot flashes, nausea, vomiting, skin rash
Endometrial hyperplasia/carcinoma (due to ER agonism in endometrium)
Thromboembolism (DVT, PE)
QT prolongation - avoid with other QT-prolonging agents (amiodarone, clarithromycin, trazodone)
Visual disturbances

2. Raloxifene

Feature	Detail
Class	Polyhydroxylated nonsteroidal compound with a benzothiophene core
Receptor action	Antagonist in breast and uterus; agonist in bone
Uses	Prevention and treatment of postmenopausal osteoporosis; reduce risk of ER+ invasive breast cancer in postmenopausal women
Bone effect	Inhibits bone resorption; reduces vertebral fracture risk ~30-50%; does NOT reduce hip fracture risk
Lipid effect	Lowers serum total cholesterol and LDL
Key advantage over tamoxifen	No estrogenic activity in endometrium → does NOT increase endometrial cancer risk; less vaginal discharge

Adverse effects:

Hot flashes, leg cramps
DVT (absolute risk ~1 in 400, similar to oral estrogen HRT)
Associated with increased risk of fatal stroke in high-baseline-risk women (caution in women >65)

3. Clomiphene

Feature	Detail
Isomers	Zuclomiphene (cis; weak agonist) + Enclomiphene (trans; potent antagonist)
Mechanism	Acts as a partial ER agonist/antagonist at the hypothalamus; blocks negative estrogen feedback → increases GnRH and gonadotropin (FSH/LH) secretion → stimulates ovulation
Use	Treatment of infertility in anovulatory women

4. Bazedoxifene

Feature	Detail
Action	Antagonizes estrogen at the uterus (reduces endometrial hyperplasia)
Available as	Fixed combination with conjugated equine estrogens (DUAVEE) for menopausal symptoms in women with intact uterus
Fracture data	Reduces vertebral fractures by ~42%

5. Ospemifene

Indicated for dyspareunia (painful intercourse) related to menopause.

Chemical Structures

Tissue-Selective Summary Table

Drug	Breast	Uterus	Bone	Uses
Tamoxifen	Antagonist	Agonist	Agonist	Breast cancer Tx/prophylaxis
Raloxifene	Antagonist	Antagonist	Agonist	Osteoporosis, breast cancer prophylaxis
Clomiphene	Antagonist (hypothalamus)	-	-	Infertility/anovulation
Bazedoxifene	Antagonist	Antagonist	Agonist	Menopausal symptoms + osteoporosis
Ospemifene	Antagonist	Mixed	-	Menopausal dyspareunia

Pharmacokinetics (Class)

All SERMs are orally active and rapidly absorbed.
Tamoxifen: extensive hepatic CYP metabolism with active metabolites; CYP3A4/CYP2D6.
Raloxifene: rapid conversion to glucuronide conjugates (first-pass metabolism).
Both undergo enterohepatic recycling; primary excretion via bile into feces.

SERMs vs. SERDs vs. Aromatase Inhibitors

For ER+/PR+ breast cancer, three major antiestrogen strategies exist:

SERMs (e.g., tamoxifen): competitive ER blockade, tissue-selective
SERDs (e.g., fulvestrant): pure ER antagonists that cause receptor downregulation - no agonist activity in any tissue
AIs (e.g., anastrozole, letrozole, exemestane): reduce estrogen synthesis in postmenopausal women by blocking peripheral aromatization

Sources: Lippincott Illustrated Reviews Pharmacology, p. 838-839; Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 987-988; Goldman-Cecil Medicine, p. 784-786

This is a shared conversation. Sign in to Orris to start your own chat.